Brief: Viracta Therapeutics Pivotal Trial Achieves Efficacy Threshold For Expansion In Ebv-Positive Peripheral T-Cell Lymphoma

Viracta Therapeutics

28/06/2023 13:56

June 28 (Reuters) - Viracta Therapeutics Inc  VIRX.O :
    * VIRACTA THERAPEUTICS’ PIVOTAL NAVAL-1 TRIAL ACHIEVES
EFFICACY
THRESHOLD FOR EXPANSION IN RELAPSED OR REFRACTORY EBV-POSITIVE
PERIPHERAL T-CELL LYMPHOMA (R/R EBV+ PTCL)
    * VIRACTA THERAPEUTICS INC - NAVAL-1 ENROLLMENT CONTINUES
WORLDWIDE WITH UPDATES ON POTENTIAL ADDITIONAL COHORT
ADVANCEMENTS EXPECTED IN H2 OF 2023

Source text for Eikon:  ID:nGNX2rnWG6 
Further company coverage:  VIRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))